Results 141 to 150 of about 391,439 (237)

Exploring the Association Between Intra‐Patient Variability in Trough Concentration of Pazopanib and Clinical Outcomes in Renal Cell Carcinoma and Soft Tissue Sarcoma Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Pazopanib is an oral tyrosine kinase inhibitor used in patients with either metastatic renal cell carcinoma or soft tissue sarcoma. Pazopanib has a high interindividual variability in pharmacokinetics and pharmacodynamics and a well‐established exposure–response relationship. Therefore, therapeutic drug monitoring is recommended to improve the efficacy–
Amy Rieborn, Eline L. Giraud, Teun van Gelder, Hans Gelderblom, Nielka P. van Erp, Tom van der Hulle, Dirk Jan A. R. Moes   +6 more
wiley   +1 more source

Gastrointestinal clear cell sarcoma, AKA malignant gastrointestinal Neuroectodermal tumor: an uncommon entity in a young patient presenting with Anemia, Intraabdominal mass and subsequent liver metastasis. [PDF]

Oxf Med Case Reports
Salehiazar S, Grujic S.
europepmc   +1 more source

The Myriad Spectrum of Salivary Gland Lesions: Cytohistological Correlation on Fine Needle Aspiration Cytology, Core Needle Biopsy, and Resections in a 5‐Year Single Institutional Experience of North India

Diagnostic Cytopathology, EarlyView.
ABSTRACT Introduction Fine needle aspiration cytology (FNAC) is a cost‐effective method used for preoperative diagnosis of salivary gland lesions. Due to the wide range of tumor types, overlapping morphology, and limited cellularity, diagnosing salivary gland lesions on FNAC can be challenging.
Zachariah Chowdhury, Pallavi Majumdar, Sumeet Narain, Komal Lamba   +3 more
wiley   +1 more source

Genomic, transcriptomic, and immunogenomic landscape of over 1300 sarcomas of diverse histology subtypes. [PDF]

Nat Commun
Soupir A, Ospina OE, Hampton O, Churchman M, Radmacher M, Hedges D, McKean D, Agius P, Zeeshan S, Seligson ND, Pollock R, Liebner D, Chen JL, Tinoco G, Salhia B, McCarter M, Wilky BA, Miller BJ, Cavnar MJ, Groundland JS, Schneider BP, Riedlinger G, Edge SB, Moskaluk CA, Cardona K, Naqash AR, Gonzalez RJ, Mullinax JE, Joyce DM, Binitie O, Douglas Letson G, Naghavi AO, Druta M, Reed DR, Siegel EM, Teer JK, Fridley BL, Brohl AS.   +37 more
europepmc   +1 more source

Rodent monocyte‐derived macrophages do not express CD163: Comparative analysis using macrophages from living boreoeutherians

Developmental Dynamics, EarlyView.
Abstract Background CD163 is a scavenger receptor predominantly expressed on the surfaces of macrophages in various mammalian species and is a marker of anti‐inflammatory (M2‐like) macrophages. High density of CD163‐positive tumor‐associated macrophages (TAMs) is associated with worse prognosis in various patient tumors.
Yoichi Saito, Yukio Fujiwara, Yasuka L. Yamaguchi, Satomi S. Tanaka, Kyoko Miura, Yoshiyuki Hizukuri, Kyoko Yamashiro, Yasuhiro Hayashi, Yuta Nakashima, Yoshihiro Komohara   +9 more
wiley   +1 more source

Primary sarcoma of the prostate: A case series of 6 patients. [PDF]

Medicine (Baltimore)
Yang P, Wang L, He Y.
europepmc   +1 more source

Cancer therapy‐related cardiotoxicity is associated with distinct alterations of the myocardial lipidome

European Journal of Heart Failure, EarlyView.
Lipidome changes in anthracycline‐induced cardiotoxicity (AIC). Aims Anthracyclines are key components of various chemotherapy regimens, but their clinical utility is limited by severe cardiotoxic side effects. Previous studies have suggested that anthracycline‐induced cardiotoxicity (AIC) may be driven by alterations in myocardial lipid metabolism ...
Vera M. Braun, Anna Foryst‐Ludwig, Ulf Landmesser, István Baczkó, Hendrik Milting, Ulrich Kintscher, Niklas Beyhoff   +6 more
wiley   +1 more source

Pediatic intracranial synovial sarcoma: a case report. [PDF]

Discov Oncol
Liu M, Fan M, Li D, Zhang G, Li Q.
europepmc   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

Recurrent Kaposi sarcoma associated with Koebner phenomenon in two HIV-seronegative patients [PDF]

, 2017
Alaibac, Mauro, Calabr\uf2, Maria Luisa, Calabrese, Fiorella, La Torre, Fabio Biagio, Marino, Dario, Ottaviano, Giancarlo, Vicario, Mattia   +6 more
core   +1 more source